Chargement des cours...
Prévisions
L'objectif de cours moyen des analystes est de 1,98 € (-80,68 %). La médiane est de 1,82 € (-82,24 %).
| Acheter |
3 |
| Conserver |
13 |
| Vendre |
2 |
Discussions dans la communauté
- Ticker Symbol neben ISIN und WKN
Hallo zusammen, wenn möglich würde ich gerne parallel zur ISIN und WKN das zugehörige Tickersymbol in der Übersicht zum Wertpapier sehen: Beispiele Aktie Amarin Co. ADR ISIN US0231112063 WKN A0NBNG…
OM Olaf Müller IV dans Portfolio Tracking
3 2
Actualités Accéder au fil d'actualités
Amarin reports 42% revenue decline after missing prior-year license payment
Amarin reported a 42% decline in net revenues for Q2, mainly due to the absence of a $25m license prepayment from Recordati in the prior-year period. Operating expenses fell 59% to $27m after completing a $70m cost‑reduction initiative. US sales of VASCEPA decreased slightly because of generic competition and net price pressure, partly offset by demand; the company recorded its third consecutive quarter of positive cash flow and expects international growth, stable US sales volumes, positive cash flow and a 10% increase in liquid funds by the end of 2026. » Plus sur de.investing.com
Amarin emphasizes cost advantage of VASCEPA after approval of new injectable therapies
Amarin clarifies that VASCEPA remains a treatment option for severe hypertriglyceridemia and reduced triglycerides by a median of 33% versus placebo. About 50% of patients reached levels below 500 mg/dL after 12 weeks. The company highlights that the annual wholesale prices of the new injectable APOC3 therapies are around $40,000, while VASCEPA costs about $4,200 per patient. Amarin also points to over 30 million prescriptions and the cardiovascular approval in combination with statins. » Plus sur de.investing.com
Amarin shareholders block share issuances and restrict equity compensation
Amarin shareholders rejected several key proposals, including the renewal of the authorization to issue new shares, an increase in the reserve under the 2020 Stock Incentive Plan, and the issuance of shares without UK pre-emption rights. While the re-election of several board members and the advisory approval of executive pay were passed, they received lower support levels. The board warns this will severely limit the grant of equity-based incentives, make future variable pay primarily cash‑based, and incur additional costs for paper shareholder communications. Shareholders approved the appointment of Ernst & Young as auditor for fiscal year 2026. » Plus sur de.investing.com
Amarin increases sales and reduces operating loss through restructuring
Amarin reported a 7.4% increase in total net revenue for Q1 2026 to $45.1 million and, thanks to restructuring measures, cut operating expenses by 31%. The operating loss fell 32.7% to $11.3 million. The company generated positive cash flow for the second consecutive quarter ($6.4 million) and held $308 million in cash at quarter-end. Vascepa prescriptions in the US rose 17%, and the partnership with Recordati contributed to strong revenue growth in Europe. Amarin expects positive full-year cash flow for 2026 and forecasts Q2 EPS of $0.54, but notes risks from generic competition and regulatory hurdles. » Plus sur de.investing.com
Amarin to release quarterly results on Feb. 25, 2026
Amarin will release results for the quarter ended Dec. 31, 2025 on Feb. 25, 2026. Three analysts see an average EPS of $0.034 per share, after a loss of -$2.380 in the year-ago quarter. The consensus expects quarterly revenue of $54.6 million (‑11.6% vs. $61.7 million a year earlier). For the fiscal year, three analysts on average forecast a loss of -$0.661 per share and revenue of $222.5 million compared with $228.7 million the prior year. » Plus sur finanzen.net
Dividendes historiques Dividendes
Tous les indicateurs de dividendes Tous les indicateursDonnées financières de l'entreprise
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 34,92 M | 17,50 % |
| Bénéfice brut | 14,29 M | 24,51 % |
| Bénéfice net | 216,3 k | 103,28 % |
| EBITDA | 842,24 k | 219,08 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 213,04 M € |
Nombre d'actions | 20,68 M |
Plus haut/bas sur 52 semaines | 15,76 € - 10,25 € |
| Dividendes | Non |
Bêta | 0,79 |
Ratio P/E | -10,80 |
Ratio PEG | -0,07 |
Ratio P/B | 0,53 |
Ratio P/S | 1,33 |
Profil de l'entreprise
Amarin Corporation plc, une société pharmaceutique, se consacre au développement et à la commercialisation de traitements destinés à la prise en charge des maladies cardiovasculaires aux États-Unis, en Allemagne, au Canada, au Liban et aux Émirats arabes unis. Son produit phare est VASCEPA, un produit à base d'acides gras oméga-3 disponible uniquement sur ordonnance, utilisé en complément d'un régime alimentaire pour réduire les taux de triglycérides chez les patients adultes atteints d'hypertriglycéridémie sévère. La société vend ses produits principalement à des grossistes et à des prestataires de pharmacies spécialisées. Elle collabore avec Mochida Pharmaceutical Co., Ltd. afin de développer et commercialiser des médicaments et des indications fondés sur le principe actif de Vascepa, l'acide oméga-3, et sur l'acide eicosapentaénoïque. La société était auparavant connue sous le nom d'Ethical Holdings plc et a changé de dénomination pour devenir Amarin Corporation plc en 1999. Amarin Corporation plc a été constituée en 1989 et son siège social se trouve à Dublin, en Irlande.
| Nom | Amarin Co. ADR |
| PDG | Aaron D. Berg |
| Siège social | Dublin,
du Irlande |
| Site web | |
| Secteur | Matériaux |
| Industrie | Produits chimiques |
| Introduction en bourse | 01/04/1993 |
| Employés | 80 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | AMRN |
Frankfurt | EH3A.F |
Düsseldorf | EH3A.DU |
München | EH3A.MU |